These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 35105722)
1. Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial. Sun F; Huang W; Chen J; Zhao L; Zhang D; Wang X; Wan W; Dai SM; Chen S; Li T; Ye S Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35105722 [TBL] [Abstract][Full Text] [Related]
2. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval. Loncharich MF; Anderson CW ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Navarra SV; Guzmán RM; Gallacher AE; Hall S; Levy RA; Jimenez RE; Li EK; Thomas M; Kim HY; León MG; Tanasescu C; Nasonov E; Lan JL; Pineda L; Zhong ZJ; Freimuth W; Petri MA; Lancet; 2011 Feb; 377(9767):721-31. PubMed ID: 21296403 [TBL] [Abstract][Full Text] [Related]
4. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF; Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708 [TBL] [Abstract][Full Text] [Related]
5. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822 [TBL] [Abstract][Full Text] [Related]
6. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW; Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628 [TBL] [Abstract][Full Text] [Related]
7. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. Jones A; Muller P; Dore CJ; Ikeji F; Caverly E; Chowdhury K; Isenberg DA; Gordon C; Ehrenstein MR BMJ Open; 2019 Dec; 9(12):e032569. PubMed ID: 31848169 [TBL] [Abstract][Full Text] [Related]
8. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial. Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180 [No Abstract] [Full Text] [Related]
9. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Zhang F; Bae SC; Bass D; Chu M; Egginton S; Gordon D; Roth DA; Zheng J; Tanaka Y Ann Rheum Dis; 2018 Mar; 77(3):355-363. PubMed ID: 29295825 [TBL] [Abstract][Full Text] [Related]
10. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Wallace DJ; Stohl W; Furie RA; Lisse JR; McKay JD; Merrill JT; Petri MA; Ginzler EM; Chatham WW; McCune WJ; Fernandez V; Chevrier MR; Zhong ZJ; Freimuth WW Arthritis Rheum; 2009 Sep; 61(9):1168-78. PubMed ID: 19714604 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study. Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533 [TBL] [Abstract][Full Text] [Related]
12. The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study. Bae SC; Bass DL; Chu M; Curtis P; Dimelow R; Harvey L; Ji B; Kurrasch R; Muzaffar S; Punwaney R; Roth DA; Song YW; Xie W; Zhang F Arthritis Res Ther; 2022 Feb; 24(1):46. PubMed ID: 35172878 [TBL] [Abstract][Full Text] [Related]
13. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Manzi S; Sánchez-Guerrero J; Merrill JT; Furie R; Gladman D; Navarra SV; Ginzler EM; D'Cruz DP; Doria A; Cooper S; Zhong ZJ; Hough D; Freimuth W; Petri MA; Ann Rheum Dis; 2012 Nov; 71(11):1833-8. PubMed ID: 22550315 [TBL] [Abstract][Full Text] [Related]
14. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States. Furie RA; Wallace DJ; Aranow C; Fettiplace J; Wilson B; Mistry P; Roth DA; Gordon D Arthritis Rheumatol; 2018 Jun; 70(6):868-877. PubMed ID: 29409143 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of metformin in systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial. Sun F; Wang HJ; Liu Z; Geng S; Wang HT; Wang X; Li T; Morel L; Wan W; Lu L; Teng X; Ye S Lancet Rheumatol; 2020 Apr; 2(4):e210-e216. PubMed ID: 38268156 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus. Doria A; Stohl W; Schwarting A; Okada M; Scheinberg M; van Vollenhoven R; Hammer AE; Groark J; Bass D; Fox NL; Roth D; Gordon D Arthritis Rheumatol; 2018 Aug; 70(8):1256-1264. PubMed ID: 29671280 [TBL] [Abstract][Full Text] [Related]
17. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Kalunian KC; Merrill JT; Maciuca R; McBride JM; Townsend MJ; Wei X; Davis JC; Kennedy WP Ann Rheum Dis; 2016 Jan; 75(1):196-202. PubMed ID: 26038091 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo-controlled trial in North East Asia. Suh CH; Lee Y; Yoo SB; Quasny H; Navarro Rojas AA; Hammer A; Song YW; Kang YM; Cho CS; Park W; Kwok SK; Lee SG; Chung WT; Bae SC Int J Rheum Dis; 2024 Jan; 27(1):e14997. PubMed ID: 38140854 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. Brunner HI; Abud-Mendoza C; Mori M; Pilkington CA; Syed R; Takei S; Viola DO; Furie RA; Navarra S; Zhang F; Bass DL; Eriksson G; Hammer AE; Ji BN; Okily M; Roth DA; Quasny H; Ruperto N RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304 [TBL] [Abstract][Full Text] [Related]
20. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis. Wilkinson C; Henderson RB; Jones-Leone AR; Flint SM; Lennon M; Levy RA; Ji B; Bass DL; Roth D Arthritis Res Ther; 2020 May; 22(1):102. PubMed ID: 32366280 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]